Business
New Research Collaboration
New Research Collaboration.
About this update from Genflow Biosciences Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3107G\n Genflow Biosciences PLC\n 29 March 2022\n \n \n \n \n \n \n \n PRESS RELEASE\n \n \n 29 March 2022\n \n \n Genflow Biosciences Plc\n \n \n (\"Genflow\" or \"the Company\")\n \n \n \n \n \n \n New Research Collaboration with the University of \n \n \n Rochester's Aging Research Center\n \n \n \n Opportunity to Demonstrate the Reversal of the Aging Process in Liver Tissue\n \n \n Genflow (LSE: GENF) is pleased to announce it has commenced a scientific research collaboration with the University of \n Rochester's Aging Research Center\n \n (RoAR). This collaboration will initially research the potential of \n Sirtuin-6 (\"SIRT6\") in \n reversing the aging process in liver tissue. This is the first step towards a true rejuvenation gene therapy across a range of tissues.\n \n \n RoAR is one of the world's pre-eminent age research facilities. The collaborative research will be spearheaded by a member of the Company's scientific advisory board, Dr Vera Gorbunova, who is also a co-director of RoAR and an internationally acclaimed leading scientist in the areas of DNA repair and the aging process. Dr Gorbunova has received awards from The Ellison Medical Foundation, The Glenn Foundation, American Federation for Aging Research and the National Institute of Health. \n \n \n \n \n \n The SIRT6 gene variant found in centenarians (people aged more than 100 years old) has previously demonstrated significant capabilities in epigenetic tissue rejuvenation. The ability of SIRT6 to act on the rejuvenation of cells is a significant finding, indicative of the SIRT6 gene mutation's potential to not just halt the aging process, but to reverse it.\n \n \n While the research collaboration will initially explore the ability of gene therapy for the rejuvenation of the liver, it could have significant implications beyond liver tissue and may indicate SIRT6's potential across a range of tissue rejuvenation and, for longevity research, more widely. The data obtained from the collaboration will support the pre-clinical trials Genflow is undertaking and will expedite its development of gene therapies.\n \n \n Genflow is \n a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age. It is t...